# Creative Medical Technology Holdings, Inc.: financial statements, quarterly

CELZ · Nasdaq · CIK 1187953 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/celz.md) · [Financials](/companies/celz/financials.md) · [Filings](/companies/celz/filings.md) · [Insiders](/companies/celz/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/celz/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [6.0](/filings/0001477932-24-006991.md) | [3.0 d](/filings/0001477932-25-001736.md) | [0.0](/filings/0001477932-25-003498.md) | [8.0](/filings/0001477932-25-005614.md) | [0.0](/filings/0001477932-25-007978.md) | [3.0 d](/filings/0001477932-26-001517.md) | [3.0](/filings/0001477932-26-002893.md) | [0.0](/filings/0001477932-26-004779.md) | [0.0](/filings/0001477932-25-007978.md) | [3.0 d](/filings/0001477932-26-001517.md) | [0.0](/filings/0001477932-26-002893.md) | [0.0](/filings/0001477932-26-004779.md) |
| Cost of revenue | $k | [2.4](/filings/0001477932-24-006991.md) | [1.2 d](/filings/0001477932-25-001736.md) | [0.0](/filings/0001477932-25-003498.md) | [3.2](/filings/0001477932-25-005614.md) | [0.0](/filings/0001477932-25-007978.md) | [1.2 d](/filings/0001477932-26-001517.md) | [1.2](/filings/0001477932-26-002893.md) | [0.0](/filings/0001477932-26-004779.md) | [0.0](/filings/0001477932-25-007978.md) | [1.0 d](/filings/0001477932-26-001517.md) | [0.0](/filings/0001477932-26-002893.md) | [0.0](/filings/0001477932-26-004779.md) |
| Gross profit | $k | [3.6](/filings/0001477932-24-006991.md) | [1.8 d](/filings/0001477932-25-001736.md) | [0.0](/filings/0001477932-25-003498.md) | [4.8](/filings/0001477932-25-005614.md) | [0.0](/filings/0001477932-25-007978.md) | [1.8 d](/filings/0001477932-26-001517.md) | [1.8](/filings/0001477932-26-002893.md) | [0.0](/filings/0001477932-26-004779.md) | [0.0](/filings/0001477932-25-007978.md) | [2.0 d](/filings/0001477932-26-001517.md) | [0.0](/filings/0001477932-26-002893.md) | [0.0](/filings/0001477932-26-004779.md) |
| Research and development | $k | [993](/filings/0001477932-24-006991.md) | [349 d](/filings/0001477932-25-001736.md) | [422](/filings/0001477932-25-003498.md) | [925](/filings/0001477932-25-005614.md) | [582](/filings/0001477932-25-007978.md) | [472 d](/filings/0001477932-26-001517.md) | [743](/filings/0001477932-26-002893.md) | [501](/filings/0001477932-26-004779.md) | [465](/filings/0001477932-25-007978.md) | [550 d](/filings/0001477932-26-001517.md) | [542](/filings/0001477932-26-002893.md) | [459](/filings/0001477932-26-004779.md) |
| Selling, general and administrative | $k | [531](/filings/0001477932-24-006991.md) | [1,399 d](/filings/0001477932-25-001736.md) | [671](/filings/0001477932-25-003498.md) | [676](/filings/0001477932-25-005614.md) | [499](/filings/0001477932-25-007978.md) | [1,393 d](/filings/0001477932-26-001517.md) | [888](/filings/0001477932-26-002893.md) | [732](/filings/0001477932-26-004779.md) | [777](/filings/0001477932-25-007978.md) | [1,367 d](/filings/0001477932-26-001517.md) | [889](/filings/0001477932-26-002893.md) | [1,080](/filings/0001477932-26-004779.md) |
| Operating income | $k | [(1,543)](/filings/0001477932-24-006991.md) | [(1,772) d](/filings/0001477932-25-001736.md) | [(1,123)](/filings/0001477932-25-003498.md) | [(1,625)](/filings/0001477932-25-005614.md) | [(1,110)](/filings/0001477932-25-007978.md) | [(1,886) d](/filings/0001477932-26-001517.md) | [(1,660)](/filings/0001477932-26-002893.md) | [(1,264)](/filings/0001477932-26-004779.md) | [(1,273)](/filings/0001477932-25-007978.md) | [(1,946) d](/filings/0001477932-26-001517.md) | [(1,459)](/filings/0001477932-26-002893.md) | [(1,562)](/filings/0001477932-26-004779.md) |
| Interest expense | $k | not reported | not reported | [0.0](/filings/0001477932-24-002695.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [0.0](/filings/0001477932-23-008458.md) | [0.0 d](/filings/0001477932-25-001736.md) | [0.0](/filings/0001477932-25-003498.md) | [0.0](/filings/0001477932-25-005614.md) | [0.0](/filings/0001477932-25-007978.md) | [0.0 d](/filings/0001477932-26-001517.md) | [0.0](/filings/0001477932-26-002893.md) | [0.0](/filings/0001477932-26-004779.md) | [0.0](/filings/0001477932-25-007978.md) | [0.0 d](/filings/0001477932-26-001517.md) | [0.0](/filings/0001477932-26-002893.md) | [0.0](/filings/0001477932-26-004779.md) |
| Net income | $k | [(1,454)](/filings/0001477932-24-006991.md) | [(1,679) d](/filings/0001477932-25-001736.md) | [(1,042)](/filings/0001477932-25-003498.md) | [(1,558)](/filings/0001477932-25-005614.md) | [(1,040)](/filings/0001477932-25-007978.md) | [(1,854) d](/filings/0001477932-26-001517.md) | [(1,638)](/filings/0001477932-26-002893.md) | [(1,233)](/filings/0001477932-26-004779.md) | [(1,236)](/filings/0001477932-25-007978.md) | [(1,888) d](/filings/0001477932-26-001517.md) | [(1,405)](/filings/0001477932-26-002893.md) | [(1,512)](/filings/0001477932-26-004779.md) |
| Diluted EPS | $ per share | not reported | not reported | [0.73](/filings/0001477932-25-003498.md) | [(1.11)](/filings/0001477932-25-005614.md) | [(0.75)](/filings/0001477932-25-007978.md) | not reported | [(0.83)](/filings/0001477932-26-002893.md) | [(0.48)](/filings/0001477932-26-004779.md) | [(0.48)](/filings/0001477932-25-007978.md) | not reported | [(0.38)](/filings/0001477932-26-002893.md) | [(0.41)](/filings/0001477932-26-004779.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.5](/filings/0001477932-23-008458.md) | [3.5](/filings/0001477932-24-001431.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [12.0](/filings/0001477932-23-008458.md) | [10.3](/filings/0001477932-25-001736.md) | [9.2](/filings/0001477932-24-002695.md) | [7.6](/filings/0001477932-24-004635.md) | [6.3](/filings/0001477932-24-006991.md) | [6.1](/filings/0001477932-26-001517.md) | [7.8](/filings/0001477932-25-003498.md) | [6.6](/filings/0001477932-25-005614.md) | [5.4](/filings/0001477932-25-007978.md) | [7.4](/filings/0001477932-26-004779.md) | [6.1](/filings/0001477932-26-002893.md) | [9.0](/filings/0001477932-26-004779.md) |
| Total assets | $m | [12.5](/filings/0001477932-23-008458.md) | [10.7](/filings/0001477932-25-001736.md) | [9.6](/filings/0001477932-24-002695.md) | [8.0](/filings/0001477932-24-004635.md) | [6.9](/filings/0001477932-24-006991.md) | [6.7](/filings/0001477932-26-001517.md) | [8.3](/filings/0001477932-25-003498.md) | [7.1](/filings/0001477932-25-005614.md) | [5.9](/filings/0001477932-25-007978.md) | [7.8](/filings/0001477932-26-004779.md) | [6.4](/filings/0001477932-26-002893.md) | [9.4](/filings/0001477932-26-004779.md) |
| Current liabilities | $m | [0.4](/filings/0001477932-23-008458.md) | [0.4](/filings/0001477932-25-001736.md) | [0.4](/filings/0001477932-24-002695.md) | [0.4](/filings/0001477932-24-004635.md) | [0.3](/filings/0001477932-24-006991.md) | [0.3](/filings/0001477932-26-001517.md) | [0.3](/filings/0001477932-25-003498.md) | [0.3](/filings/0001477932-25-005614.md) | [0.3](/filings/0001477932-25-007978.md) | [0.3](/filings/0001477932-26-004779.md) | [0.3](/filings/0001477932-26-002893.md) | [0.7](/filings/0001477932-26-004779.md) |
| Total liabilities | $m | [0.4](/filings/0001477932-23-008458.md) | [0.4](/filings/0001477932-25-001736.md) | [0.4](/filings/0001477932-24-002695.md) | [0.4](/filings/0001477932-24-004635.md) | [0.3](/filings/0001477932-24-006991.md) | [0.3](/filings/0001477932-26-001517.md) | [0.3](/filings/0001477932-25-003498.md) | [0.3](/filings/0001477932-25-005614.md) | [0.3](/filings/0001477932-25-007978.md) | [0.3](/filings/0001477932-26-004779.md) | [0.3](/filings/0001477932-26-002893.md) | [0.7](/filings/0001477932-26-004779.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [12.1](/filings/0001477932-24-006991.md) | [10.3](/filings/0001477932-25-007978.md) | [9.2](/filings/0001477932-25-005614.md) | [7.6](/filings/0001477932-25-007978.md) | [6.6](/filings/0001477932-25-007978.md) | [6.3](/filings/0001477932-26-001517.md) | [8.1](/filings/0001477932-25-005614.md) | [6.8](/filings/0001477932-25-007978.md) | [5.6](/filings/0001477932-25-007978.md) | [7.5](/filings/0001477932-26-004779.md) | [6.1](/filings/0001477932-26-002893.md) | [8.7](/filings/0001477932-26-004779.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,305) d](/filings/0001477932-24-006991.md) | [(1,895) d](/filings/0001477932-25-001736.md) | [(897)](/filings/0001477932-25-003498.md) | [(1,469) d](/filings/0001477932-25-005614.md) | [(986) d](/filings/0001477932-25-007978.md) | [(1,950) d](/filings/0001477932-26-001517.md) | [(1,592)](/filings/0001477932-26-002893.md) | [(1,159) d](/filings/0001477932-26-004779.md) | [(1,169) d](/filings/0001477932-25-007978.md) | [(1,938) d](/filings/0001477932-26-001517.md) | [(1,323)](/filings/0001477932-26-002893.md) | [(1,472) d](/filings/0001477932-26-004779.md) |
| Share repurchases | $k | [192 d](/filings/0001477932-24-006991.md) | [79.2 d](/filings/0001477932-25-001736.md) | [82.8](/filings/0001477932-25-003498.md) | [66.7 d](/filings/0001477932-25-005614.md) | [25.5 d](/filings/0001477932-25-007978.md) | [0.0 d](/filings/0001477932-26-001517.md) | [10.0](/filings/0001477932-26-002893.md) | [0.0 d](/filings/0001477932-26-004779.md) | [0.0 d](/filings/0001477932-25-007978.md) | [0.0 d](/filings/0001477932-26-001517.md) | [0.0](/filings/0001477932-26-002893.md) | [0.0 d](/filings/0001477932-26-004779.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2020 (2020-09-30) | Q1 FY2021 (2021-03-31) | Q3 FY2021 (2021-09-30) | Q3 FY2022 (2022-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.5](/filings/0001477932-21-008404.md) | [1,245](/filings/0001477932-22-003286.md) | [2.5](/filings/0001477932-22-008323.md) | [14.1](/filings/0001477932-22-008323.md) | [1.4](/filings/0001477932-25-003498.md) | [1.4](/filings/0001477932-25-005614.md) | [1.4](/filings/0001477932-25-007978.md) | [2.0](/filings/0001477932-26-002893.md) | [2.6](/filings/0001477932-26-004779.md) | [2.6](/filings/0001477932-25-007978.md) | [3.7](/filings/0001477932-26-002893.md) | [3.7](/filings/0001477932-26-004779.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,592,557 at 2026-08-07, from the cover of the [10-Q filed 2026-08-07](/filings/0001477932-26-004779.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.